BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014;167:215-23. [PMID: 24995890 DOI: 10.1016/j.jad.2014.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M. Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat 2018;14:103-15. [PMID: 29343962 DOI: 10.2147/NDT.S146840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
2 Miranda MA, Marin ML. Photocatalytic functionalization for the synthesis of drugs and analogs. Current Opinion in Green and Sustainable Chemistry 2017;6:139-49. [DOI: 10.1016/j.cogsc.2017.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang S, Han C, Pae C. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opinion on Investigational Drugs 2015;24:445-53. [DOI: 10.1517/13543784.2014.985784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;20:1142-50. [PMID: 26148812 DOI: 10.1038/mp.2015.92] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
5 Kent JM, Daly E, Kezic I, Lane R, Lim P, De Smedt H, De Boer P, Van Nueten L, Drevets WC, Ceusters M. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry 2016;67:66-73. [PMID: 26804646 DOI: 10.1016/j.pnpbp.2016.01.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
6 Zhou Y, Wang J, Gu Z, Wang S, Zhu W, Aceña JL, Soloshonok VA, Izawa K, Liu H. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chem Rev 2016;116:422-518. [PMID: 26756377 DOI: 10.1021/acs.chemrev.5b00392] [Cited by in Crossref: 1271] [Cited by in F6Publishing: 881] [Article Influence: 254.2] [Reference Citation Analysis]
7 Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 2015;14:1587-608. [PMID: 26360500 DOI: 10.1517/14740338.2015.1085970] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Ball SG, Atkinson S, Sparks J, Bangs M, Goldberger C, Dubé S. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment. Journal of Clinical Psychopharmacology 2015;35:266-72. [DOI: 10.1097/jcp.0000000000000302] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]